Potential usefulness of serum p53 for laboratory management of plasma cell dyscrasias

We measured the serum levels of p53 mutant protein (p53M-ELISA) in 65 patients with plasma cell dyscrasia (PCD) and compared them with some conventional laboratory variables. Our aim was to assess, for the first time, the potential of this parameter as a new marker for laboratory management of PCD....

Full description

Saved in:

Bibliographic Details
Published in:	Journal of experimental & clinical cancer research Vol. 22; no. 4; p. 607
Main Authors:	Greco, C, Alvino, S, Del Monte, G, Venturo, I, Lopez, M
Format:	Journal Article
Language:	English
Published:	England 01-12-2003
Subjects:	Aged Aged, 80 and over Female Humans Male Melphalan - therapeutic use Middle Aged Multiple Myeloma - blood Multiple Myeloma - drug therapy Paraproteinemias - blood Paraproteinemias - diagnosis Paraproteinemias - drug therapy Paraproteinemias - genetics Prednisone - therapeutic use Prognosis Tumor Suppressor Protein p53 - blood Tumor Suppressor Protein p53 - genetics
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We measured the serum levels of p53 mutant protein (p53M-ELISA) in 65 patients with plasma cell dyscrasia (PCD) and compared them with some conventional laboratory variables. Our aim was to assess, for the first time, the potential of this parameter as a new marker for laboratory management of PCD. Twenthy-tree out of 65 patients had monoclonal gammapathy of undetermined significance (MGUS) and 42 suffered from multiple myeloma (MM). MM patients, with no prior chemotherapy consecutively entered this study. They were treated with standard regimens of Melphalan and Prednisone (MP) and were analyzed for serum p53M level from the time of diagnosis to response to therapy or death. A subgroup of nine patients was regularly monitored for changes occurring in p53M levels during MP therapy. Serum levels of p53M were elevated in MM patients compared with MGUS and healthy controls (p = 0.002). Significantly higher p53M levels were shown by MM patients refractory to chemotherapy than by responding patients (0.38 ng/ml vs 0.22 ng/ml, p = 0.05). The measurement of serum p53M in the nine patients during the course of chemotherapy correlated with disease progression or response to therapy. If confirmed on a larger series of patients, these results suggest a potential role of serum p53 mutant levels in laboratory management of PCD patients.
ISSN:	0392-9078